

CSF proteomic signatures in Alzheimer's disease across amyloid and tau biomarker subgroups

Citation for published version (APA):

Delvenne, A. C. M.-J. (2024). *CSF proteomic signatures in Alzheimer's disease across amyloid and tau biomarker subgroups*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20240920ad>

Document status and date:

Published: 01/01/2024

DOI:

[10.26481/dis.20240920ad](https://doi.org/10.26481/dis.20240920ad)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Download date: 20 Mar. 2025

Propositions belonging to the doctoral thesis

CSF proteomic signatures in Alzheimer's disease across amyloid and tau biomarker subgroups

1. Individuals with “Suspected Non-Alzheimer's disease Pathophysiology” (SNAP) and mild cognitive impairment exhibit a distinct proteomic profile compared to those with normal cognition. (*this dissertation*)
2. SNAP is a heterogeneous condition with a low frequency of APOE ϵ_4 carriers and disturbed amyloid metabolism. (*this dissertation*)
3. Distinct candidate neurodegeneration markers cannot be used interchangeably for Alzheimer's disease staging. (*this dissertation*)
4. Amyloid and tau pathologies are both associated with choroid plexus dysfunction, each mediated by different molecular mechanisms. (*this dissertation*)
5. Proteomics serves as an invaluable tool to unravel complex pathophysiological mechanisms in diseases such as Alzheimer's disease. (*impact*)
6. Cerebrospinal fluid is a more direct and brain-specific medium than blood to study Alzheimer's disease pathophysiology.
7. Precision medicine is crucial for advancing the diagnosis and treatment of neurodegenerative diseases.
8. Human and mouse studies provide complementary approaches to advance the understanding of disease mechanisms.
9. During the PhD journey, new friendships are build and flourish with each milestone, making the journey as fulfilling as the destination.
10. Chocolate's effect on cognitive performance significantly contributes to driving research efforts towards greater discovery and innovation.

Aurore Delvenne

20th of September 2024